Starbucks denies that its decision to stop selling Chicken, Maple Butter, and Egg Sandwich on June 26, a mere five days after it had been announced as a new permanent menu item, was due to FDA recall or salmonella or listeria contamination.
A Starbucks spokesperson said that the Chicken, Maple Butter, and Egg Sandwich was given a voluntary stop sell and discard order by the company because it didn't live up to the company's high standards for quality.
The quality issue that was identified by Starbucks was simply about taste or based on another issue and would not lead to food-borne illness and any reports linking the stop sale to illness are inaccurate.
The spokesperson added that Starbucks is devoted to providing high-quality products, and anytime a concern about a product or its quality is expressed, we always proceed with extreme caution.


Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Why a ‘rip-off’ degree might be worth the money after all – research study
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
Instagram Outage Disrupts Thousands of U.S. Users
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



